A review on: nutraceutical and neuropotective approaches of Momordica charantia L. fruits against neurodegenerative disease

Sanjib K. Mohanty; Yashaswi Nayak

doi:10.18203/2319-2003.ijbcp20242440

Authors

Sanjib K. Mohanty Department of Zoology, Centurion University of Technology and Mangement, Bhubaneswar, Jatani, Khordha, Odisha, India
Yashaswi Nayak Department of Zoology, Centurion University of Technology and Mangement, Bhubaneswar, Jatani, Khordha, Odisha, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20242440

Keywords:

In-vivo studies, In-vitro studies, M. charantia, Neurodegenerative diseases

Abstract

The Momordica charantia is a tropical plant, also known as bitter gourd or bitter melon, is a crucial herbal remedy with a wide range of medicinal properties. People in Indian subcontinent and China consider, M.charantia as key components to treats variety of elements such as cancer, diabetes and neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, multiple sclerosis etc. These diseases are described by degeneration or loss of selective neuron populations in a progressive manner. The two main characteristic of neurodegenerative illness are oxidative stress and inflammation, which have been studying using the variety of medicinal herbs and their derivatives. However, very few authors have reported the protective effects of M. charantia against neurodegenerative diseases. This short review focus on the neuroprotective effects of M. charantia. Based on their anti-oxidant and anti-inflammatory properties, the present study emphasizes to further explore the protective effects of M. charantia against neurodegenerative and neuroinflammatory diseases.

Metrics

Metrics Loading ...

References

Zhang F, Lin L, Xie J. A mini-review of chemical and biological properties of polysaccharides from Momordica charantia. Int J Biol Macromol. 2016;92:246-53.

Nagarani G, Abirami A, Siddhuraju P. Food prospects and nutraceutical attributes of Momordica species: a potential tropical bioresources–a review. Food Science and Human Wellness. 2014;3(3-4):117-26.

Polito L, Bortolotti M, Maiello S, Battelli MG, Bolognesi A. Plants producing ribosome-inactivating proteins in traditional medicine. Molecules. 2016;21(11):1560.

Thakur V, Kumar S, Tiwari R, Chormule SR. Yield and yield contributing traits of bitter gourd (Momordica charantia L.) genotypes. J Pharmacog Phytochem. 2018;7(3):844-6.

Wang S, Li Z, Yang G, Ho CT, Li S. Momordica charantia: a popular health-promoting vegetable with multifunctionality. Food Function. 2017;8(5):1749-62.

Keller AC, Ma J, Kavalier A, He K, Brillantes AM, Kennelly EJ. Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro. Phytomed. 2011;19(1):32-7.

Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol. 2004;93(1):123-32.

Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol. 2000;71(1-2):23-43.

Bortolotti M, Mercatelli D, Polito L. Momordica charantia, a nutraceutical approach for inflammatory related diseases. Frontiers Pharmacol. 2019;10:486.

Poolperm S, Jiraungkoorskul W. An update review on the anthelmintic activity of bitter gourd, Momordica charantia. Pharmacognosy reviews. 2017;11(21):31.

Swarna J, Ravindhran R. Agrobacterium rhizogenes–mediated hairy root induction of Momordica charantia Linn. and the detection of charantin, a potent hypoglycaemic agent in hairy roots. Res J Biotechnol. 2012;7(4):227-31.

Gupta M, Sharma S, Gautam AK, Bhadauria R. Momordica charantia Linn. (Karela): Nature’s silent healer. Int J Pharmaceutical Sci Review Research. 2011;11(1):32-7.

Sorifa AM. Nutritional compositions, health promoting phytochemicals and value added products of bitter gourd: a review. Int Food Research J. 2018;25(5):98-107.

Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. Journal of ethnopharmacology. 2004;93(1):123-32.

Behera TK, Staub JE, Behera S, Simon PW. Bitter gourd and human health. Med Aromatic Plant Sci Biotech. 2008;1(2):224-6.

Poolperm S, Jiraungkoorskul W. An update review on the anthelmintic activity of bitter gourd, Momordica charantia. Pharmacognosy Rev. 2017;11(21):31.

Poolperm S, Jiraungkoorskul W. An update review on the anthelmintic activity of bitter gourd, Momordica charantia. Pharmacognosy reviews. 2017;11(21):31.

Asna AC, Joseph J, Joseph John K. Botanical description of bitter gourd. The bitter gourd genome. 2020:7-31.

Behera TK, Behera S, Bharathi LK, John KJ, Simon PW, Staub JE. Bitter gourd: botany, horticulture, breeding. Horticultural Rev. 2010;37:101-41.

Kumar KS, Bhowmik D. Traditional medicinal uses and therapeutic benefits of Momordica charantia Linn. Int J Pharm Sci Review Res. 2010;4(3):23-8.

Anilakumar KR, Kumar GP, Ilaiyaraja N. Nutritional, pharmacological and medicinal properties of Momordica charantia. Int J Nutr Food Sciences. 2015;4(1):75-83.

Prasad V, Jain V, Girish D, Dorle AK. Wound-healing property of Momordica charantia L. fruit powder. J Herbal Pharmacotherapy. 2006;6(3-4):105-15.

Kumari P, Kumari R, Rani N, Verma RB, Verma R. Genetic divergence of bitter gourd (Momordica charantia L.) for sixteen important yield attributing traits. Current J Applied Sci Tech. 2017;23(2):1-11.

Ullah MU, Chy FK, Sarkar SK, Islam MK, Absar NA. Nutrient and phytochemical analysis of four varieties of bitter gourd (Momordica charantia) grown in Chittagong hill tracts, Bangladesh. Asian J Agricultural Res. 2011;5(3):186-93.

Abas R, Othman F, Thent ZC. Protective effect of momordica charantia fruit extract on hyperglycaemia‐induced cardiac fibrosis. Oxidative Med Cellular Longevity. 2014;2014(1):429060.

Verissimo LF, Bacchi AD, Zaminelli T, Paula GH, Moreira EG. Herbs of interest to the Brazilian Federal Government: female reproductive and developmental toxicity studies. Revista Brasileira de Farmacognosia. 2011;21:1163-71.

Choi JR, Choi JM, Lee S, Cho KM, Cho EJ, Kim HY. The protective effects of protocatechuic acid from Momordica charantia against oxidative stress in neuronal cells. Korean J Pharmacognosy. 2014;45(1):11-6.

Fang E, B Ng T. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Current molecular medicine. 2011;11(5):417-36.

Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harbor perspectives in biology. Pharmacol. 2017;9(7):a028035.

Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain Sci. 2018;8(9):177.

Akhtar MS, Athar MA, Yaqub M. Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits. Planta Medica. 1981;42(07):205-12.

Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine. 1996;2(4):349-62.

Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health-System Pharm. 2003;60(4):356-9.

Srivastava Y, Bhatt VH, Verma Y, Venkaiah K, Raval BH. Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytotherapy Research. 1993;7(4):285-9.

Chi H, Chang HY, Sang TK. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci. 2018;19(10):3082.

Kim KB, Lee S, Kang I, Kim JH. Momordica charantia ethanol extract attenuates H2O2-induced cell death by its antioxidant and anti-apoptotic properties in human neuroblastoma SK-N-MC cells. Nutrients. 2018;10(10):1368.

Tamilanban T. In vitro neuroprotective effect of charantin from Momordica charantia against neurotoxin and endoplasmic reticulum stress-induced cell death in SH-SY5Y cells. Int J Green Pharm. 2018;12(03):22-9.

Gong J, Sun F, Li Y, Zhou X, Duan Z, Duan F, Zhao L, Chen H, Qi S, Shen J. Momordica charantia polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway. Neuropharmacol. 2015;91:123-34.

Pathakota R, Chunduru S, Damu U, Pitta L. Neuroprotective effects of momordica charantia on scopolamine induced alzheimer’s disease. World J Pharm Pharm Sci. 2017;6(04):2141-55.

Joshi A, Soni P, Malviya S, Kharia A. Memory enhancing activity of Momordica charantia by scopolamine induced amnesia in rats. Int J Cog. 2017;2:11-8.

Miri A, Askari SF, Shahraki E. Examining the effects of hydro-alcoholic extract of Momordica charantia fruit on avoidance memory alterations in mice using step-through model. J Fundamental Applied Sci. 2019;11(1):101-16.

Huang HJ, Chen SL, Chang YT, Chyuan JH, Hsieh-Li HM. Administration of Momordica charantia enhances the neuroprotection and reduces the side effects of LiCl in the treatment of Alzheimer’s disease. Nutrients. 2018;10(12):1888.

Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, Shah P, Feher D, Williams PG, Nerurkar VR. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011;8:1-9.

Deng Z, Yuan C, Yang J, Peng Y, Wang W, Wang Y, Gao W. Behavioral defects induced by chronic social defeat stress are protected by Momordica charantia polysaccharides via attenuation of JNK3/PI3K/AKT neuroinflammatory pathway. Annals Translational Med. 2019;7(1):45-9.

Ishola IO, Akinyede AA, Sholarin AM. Antidepressant and anxiolytic properties of the methanolic extract of Momordica charantia Linn (Cucurbitaceae) and its mechanism of action. Drug Res. 2014;64(07):368-76.

Duan ZZ, Zhou XL, Li YH, Zhang F, Li FY, Su-Hua Q. Protection of Momordica charantia polysaccharide against intracerebral hemorrhage-induced brain injury through JNK3 signaling pathway. J Receptors Signal Transduction. 2015;35(6):523-9.

Gong J, Sun F, Li Y, Zhou X, Duan Z, Duan F, Zhao L, Chen H, Qi S, Shen J. Momordica charantia polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway. Neuropharmacol. 2015;91:123-34.

Malik ZA, Singh M, Sharma PL. Neuroprotective effect of Momordica charantia in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. J Ethnopharmacol. 2011;133(2):729-34.

Malik ZA, Tabassum N, Sharma PL. Attenuation of experimentally induced diabetic neuropathy in association with reduced oxidative-nitrosative stress by chronic administration of Momordica charantia. Advances Biosci Biotech. 2013;4(3):356-63.

Daniel P, Supe U, Roymon MG. A review on phytochemical analysis of Momordica charantia. Int J Adv Pharm Biol Chem. 2014;3(1):214-20.